Literature DB >> 21474207

[Intervention study on subacute and chronic pain in primary care: an approach to the effectiveness of neural therapy].

Olga Lóriz Peralta1, Almudena Raya Rejón, David Pérez Morales, Alfonso Girona Amores, David Vinyes Casajoana, Katia Puente de la Vega Costa.   

Abstract

OBJECTIVE: To evaluate the effectiveness of NT in reducing pain and minimising use of analgesics in patients.
DESIGN: Before and after intervention study.
SETTING: Llefià Primary Health Care centre in Badalona (Barcelona). PARTICIPANTS: Eighty-two patients between the ages of 25 and 85 years old, who suffered pain that did not disappear after a month. MAIN MEASUREMENTS: Data was collected to evaluate any change in pain and the use of analgesics in patients before intervention and then afterwards, at 2 weeks, 3 months and 6 months. This was conducted by means of interviews and use of the Visual Analogue Pain Scale (VAS).
RESULTS: Mean VAS pre-treatment: 7.94 (SD: 1.68), mean VAS after two weeks 4.63 (SD: 2.79), after 3 months 3.73 (SD: 3.17), and after 6 months 3.48 (SD: 3,27) (P<.001 in the 3 comparisons, using the Wilcoxon-test for matched data). As regards analgesic use after treatment, 74.4% of patients reduced it after 2 weeks, 76.8% after 3 months and 80% after 6 months.
CONCLUSIONS: Neural therapy can be effective in reducing pain, as well as the use of analgesics. Further clinical trials would be needed to confirm this assertion. Copyright Â
© 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21474207      PMCID: PMC7025108          DOI: 10.1016/j.aprim.2010.10.004

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  10 in total

1.  [Effectiveness of acupuncture in the treatment of pain from osteoarthritis of the knee].

Authors:  A Ferrández Infante; L García Olmos; A González Gamarra; M J Meis Meis; B M Sánchez Rodríguez
Journal:  Aten Primaria       Date:  2002-12       Impact factor: 1.137

2.  Gate control theory of pain stands the test of time.

Authors:  A H Dickenson
Journal:  Br J Anaesth       Date:  2002-06       Impact factor: 9.166

3.  [Complementary and alternative medicine: some reflections on bioethics].

Authors:  F Borrell i Carrió
Journal:  Aten Primaria       Date:  2005-04-15       Impact factor: 1.137

4.  [Complementary or alternative medicine? A dilemma for the public health system?].

Authors:  J Caminal Homar
Journal:  Aten Primaria       Date:  2005-05-15       Impact factor: 1.137

5.  Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment.

Authors:  Harald Breivik; Beverly Collett; Vittorio Ventafridda; Rob Cohen; Derek Gallacher
Journal:  Eur J Pain       Date:  2005-08-10       Impact factor: 3.931

6.  Measurement of pain.

Authors:  E C Huskisson
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

7.  The need for a new medical model: a challenge for biomedicine.

Authors:  G L Engel
Journal:  Science       Date:  1977-04-08       Impact factor: 47.728

8.  Recent concepts of pain.

Authors:  R Melzack
Journal:  J Med       Date:  1982

9.  [From scientific knowledge of clinical research to the bedside: clinical practice guidelines and their implementation].

Authors:  Marta Aymerich; Emília Sánchez
Journal:  Gac Sanit       Date:  2004 Jul-Aug       Impact factor: 2.139

10.  Patient satisfaction of primary care for musculoskeletal diseases: a comparison between Neural Therapy and conventional medicine.

Authors:  Joelle Mermod; Lorenz Fischer; Lukas Staub; André Busato
Journal:  BMC Complement Altern Med       Date:  2008-06-24       Impact factor: 3.659

  10 in total
  1 in total

1.  Emotional release and physical symptom improvement: a qualitative analysis of self-reported outcomes and mechanisms in patients treated with neural therapy.

Authors:  Heidemarie Haller; Felix J Saha; Barbara Ebner; Anna Kowoll; Dennis Anheyer; Gustav Dobos; Bettina Berger; Kyung-Eun Choi
Journal:  BMC Complement Altern Med       Date:  2018-11-27       Impact factor: 3.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.